CN106884041B - 适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法 - Google Patents
适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法 Download PDFInfo
- Publication number
- CN106884041B CN106884041B CN201510947374.9A CN201510947374A CN106884041B CN 106884041 B CN106884041 B CN 106884041B CN 201510947374 A CN201510947374 A CN 201510947374A CN 106884041 B CN106884041 B CN 106884041B
- Authority
- CN
- China
- Prior art keywords
- snp
- mutation
- haplotype
- gene mutation
- y329fs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 206010064571 Gene mutation Diseases 0.000 title abstract description 15
- 206010000014 17-alpha-hydroxylase deficiency Diseases 0.000 title abstract description 10
- 238000000034 method Methods 0.000 title abstract description 9
- 102000054766 genetic haplotypes Human genes 0.000 claims abstract description 30
- 230000035772 mutation Effects 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 4
- 102210008804 rs1004467 Human genes 0.000 claims description 2
- 102210019247 rs3824755 Human genes 0.000 claims description 2
- 102220042536 rs4919686 Human genes 0.000 claims description 2
- 102210025380 rs4919687 Human genes 0.000 claims description 2
- 102220160366 rs6162 Human genes 0.000 claims description 2
- 102220160365 rs6163 Human genes 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 239000000969 carrier Substances 0.000 abstract description 4
- 230000007812 deficiency Effects 0.000 abstract description 4
- 238000012217 deletion Methods 0.000 abstract description 3
- 230000037430 deletion Effects 0.000 abstract description 3
- 210000000349 chromosome Anatomy 0.000 description 13
- 101150051357 CYP17A1 gene Proteins 0.000 description 6
- 239000012634 fragment Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101000690100 Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101100029173 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) SNP2 gene Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 101100236128 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) LSM2 gene Proteins 0.000 description 1
- 101100094821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SMX2 gene Proteins 0.000 description 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 1
- 102100024121 U1 small nuclear ribonucleoprotein 70 kDa Human genes 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明涉及一种适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法,其特征在于,包括以下步骤:步骤(1):在患者及携带者的待检测基因上选取多个SNP位点;步骤(2):明确所述的SNP位点的基因型;步骤(3):使用软件对多个所述的SNP位点进行单倍型分析;步骤(4):找出基因突变的单倍型,得出单倍型分析的结果;步骤(5):在正常人群中对所述的结果进行验证。本发明十分适用于中国人群,可以弥补该领域的不足与缺失,十分具有实用价值。
Description
技术领域
本发明涉及一种适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法。
背景技术
除生殖细胞外,染色体在人类细胞中成对出现。其中一条染色体来自父方,另一条来自母方。但染色体在一代代的传递过程中并不是一成不变的。在精子和卵细胞形成的过程中,染色体对发生重组,即一对染色体中聚集到一起并交换片段。由此产生的杂合染色体含有这对染色体的两个成员的片段,并传递给下一代。多代之后,经过反复的重组事件,祖先染色体的片段的原有排布在非近亲结婚的人群中已被打乱。某些祖先染色体片段会在许多后代个体的DNA序列中出现。没有被重组打破的区段相互间被那些发生了重组的区域隔开。这些区段就是单倍型,遗传学家利用它可以寻找与疾病或者其它医学上的重要特征相关的基因。
17α-羟化酶/17,20碳链裂解酶缺陷症(17OHD)是先天性肾上腺皮质增生症的一种少见类型,仅占CAH的1%。由于17OHD使人体盐皮质激素、糖皮质激素和性激素分泌紊乱,临床主要表现为低肾素性高血压、低血钾性肌无力,女性性幼稚、原发性闭经及男性假两性畸形。17OHD是一种常染色体隐性遗传疾病,目前已经发现80多个CYP17A1基因突变可以导致17OHD。目前用于检测突变方法为直接测序,使用单倍体分型检测这一突变目前尚无报道。而目前广泛开展的GWAS(全基因组关联分析)技术使得检测大量的SNP分型成为可能。在此基础上可以找到与疾病相关的单倍体。
所以,一种适用于中国人群能够筛查17α羟化酶缺乏症常见基因突变的检测方法是十分具有实用价值的。
发明内容
本发明的目的是为了提供一种尤其适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法。
为了实现上述目的,本发明提供了一种适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法,其特征在于,包括以下步骤:
步骤(1):在患者及携带者的待检测基因上选取多个SNP位点;
步骤(2):明确所述的SNP位点的基因型;
步骤(3):使用软件对多个所述的SNP位点进行单倍型分析;
步骤(4):找出基因突变的单倍型,得出单倍型分析的结果;
步骤(5):在正常人群中对所述的结果进行验证。
较佳地,所述的多个SNP位点为16个SNP位点。
较佳地,所述的16个SNP位点为:
rs743572:SNP1;rs6162:SNP2;rs6163:SNP3;rs10786712:SNP4;rs3824755:SNP5;rs3781286:SNP6;rs3781287:SNP7;rs4919687:SNP8;rs743575:SNP9;rs1004467:SNP10;rs3740397:SNP11;rs4919686:SNP12;rs284848:SNP13;rs17115100:SNP14;rs284849:SNP15;rs10883783:SNP16。
较佳地,所述的待检测基因为CYP17A1基因。
较佳地,所述的软件为PHASE2.1。
较佳地,所述的基因突变为Y329fs突变。
较佳地,所述的基因突变的单倍型的碱基序列为:TCGGCGACATCTCCCT。
本发明适用于中国人群的17α羟化酶缺乏症常见基因突变的检测,弥补了该领域的不足与缺失,且本发明的研究表明,中国人群中CYP17A1-Y329fs突变是17OHD的一种常见突变。而在本发明的研究中,收集了15例17OHD患者,其中携带有Y329fs突变的患者为10例,占患者总数的66.7%,再次确认了Y329fs突变是中国人群17OHD的一种常见突变。而本发明的原理为在CYP17A1基因上找到16个SNP,通过单倍型分析发现,所有包含Y329fs突变的染色体都携带单倍体(TCGGCGACATCTCCCT。在GWAS研究的2760例正常对照中,只有一条染色体携带有上述突变型的单倍体,说明Y329fs这一突变在中国人群来源于同一个祖先。因此这一个特异的单倍型可以用来诊断Y329fs突变。最终证明TCGGCGACATCTCCCT单倍型为包含Y329FS基因突变的致病单倍型,这一突变与这个单倍型呈完全连锁关系。本发明十分适用于中国人群,可以弥补该领域的不足与缺失,十分具有实用价值。
附图说明
图1为本发明实施例中选取的16个SNP位点相互之间的连锁关系。
具体实施方式
为了能够更清楚地理解本发明的技术内容,下面对本发明的具体实施方法作进一步说明。
实施例
本发明的具体实施办法包括以下步骤:
步骤(1):在CYP17A1基因上选取16个SNP位点(平均分布于CYP17A1基因上)。选出的SNP位点如表1所示。
表1.选取的SNP位点
步骤(2):设计6对特异性的引物能够扩增出全部16个SNP,引物如表2所示,引物1F/1R扩增SNP1、2、3,引物2F/2R扩增SNP4,引物3F/3R扩增SNP5、6、7、8,引物4F/4R扩增SNP9、10,引物5F/5R扩增SNP11、12、13,引物6F/6R扩增SNP14、15、16。
表2. PCR扩增片段及引物
步骤(3):在患者及携带者(Y329fs)中对这16个SNP位点进行基因测序明确各个位点的基因型。
步骤(4):使用PHASE 2.1软件进行单倍型分析。
步骤(5):得到患者及携带者包含16个SNP位点的单倍型haplotype 1-5。如表3所示.
表3
步骤(6)最终发现TCGGCGACATCTCCCT单倍型为包含Y329FS基因突变的致病单倍型,这一突变与这个单倍型呈完全连锁关系。其连锁关系如图1所示。
步骤(7)在2760例正常汉族人群中,仅发现一个等位基因包含这一致病单倍型(携带者)。通过单倍型分析说明Y329fs这一突变在中国人群来源于同一个祖先。因此这一个特异的单倍型可以作为Y329fs突变的分子标志应用于人群中GWAS的研究来筛查此突变的携带者。
本发明适用于中国人群的17α羟化酶缺乏症常见基因突变的检测,弥补了该领域的不足与缺失,且本发明的研究表明,中国人群中CYP17A1-Y329fs突变是17OHD的一种常见突变。而在本发明的研究中,收集了15例17OHD患者,其中携带有Y329fs突变的患者为10例,占患者总数的66.7%,再次确认了Y329fs突变是中国人群17OHD的一种常见突变。而本发明的原理为在CYP17A1基因上找到16个SNP,通过单倍型分析发现,所有包含Y329fs突变的染色体都携带单倍体(TCGGCGACATCTCCCT。在GWAS研究的2760例正常对照中,只有一条染色体携带有上述突变型的单倍体,说明Y329fs这一突变在中国人群来源于同一个祖先。因此这一个特异的单倍型可以用来诊断Y329fs突变。最终证明TCGGCGACATCTCCCT单倍型为包含Y329FS基因突变的致病单倍型,这一突变与这个单倍型呈完全连锁关系。本发明十分适用于中国人群,可以弥补该领域的不足与缺失,十分具有实用价值。
在此说明书中,本发明已参照其特定的实施例作了描述。但是,很显然仍可以做出各种修改和变换而不背离本发明的精神和范围。因此,说明书应被认为是说明性的而非限制性的。
序列表
<110> 上海交通大学医学院附属第九人民医院
<120> 适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法
<140> 2015109473749
<141> 2015-12-16
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 16
<212> DNA
<213> 人工序列(化学合成)
<400> 1
tcggcgacat ctccct 16
Claims (1)
1.单倍型作为标志物在筛查中国人群CYP17A1-Y329fs突变中的应用,其特征在于,所述单倍型的碱基序列为:TCGGCGACATCTCCCT,该单倍型与Y329fs完全连锁;所述单倍型来源于16个SNP位点,分别为:rs743572:SNP1;rs6162:SNP2;rs6163:SNP3;rs10786712:SNP4;rs3824755:SNP5;rs3781286:SNP6;rs3781287:SNP7;rs4919687:SNP8;rs743575:SNP9;rs1004467:SNP10;rs3740397:SNP11;rs4919686:SNP12;rs284848:SNP13;rs17115100:SNP14;rs284849:SNP15;rs10883783:SNP16;
所述应用为非疾病诊断目的。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510947374.9A CN106884041B (zh) | 2015-12-16 | 2015-12-16 | 适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510947374.9A CN106884041B (zh) | 2015-12-16 | 2015-12-16 | 适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106884041A CN106884041A (zh) | 2017-06-23 |
CN106884041B true CN106884041B (zh) | 2021-03-09 |
Family
ID=59175843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510947374.9A Active CN106884041B (zh) | 2015-12-16 | 2015-12-16 | 适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106884041B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102812129A (zh) * | 2009-11-10 | 2012-12-05 | 麻省理工学院 | 用于从类异戊二烯途径生产化学和医药产品的微生物工程 |
CN104232753A (zh) * | 2014-07-22 | 2014-12-24 | 百世诺(北京)医疗科技有限公司 | 一种检测17α-羟化酶缺乏症相关基因突变的试剂盒 |
-
2015
- 2015-12-16 CN CN201510947374.9A patent/CN106884041B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102812129A (zh) * | 2009-11-10 | 2012-12-05 | 麻省理工学院 | 用于从类异戊二烯途径生产化学和医药产品的微生物工程 |
CN104232753A (zh) * | 2014-07-22 | 2014-12-24 | 百世诺(北京)医疗科技有限公司 | 一种检测17α-羟化酶缺乏症相关基因突变的试剂盒 |
Non-Patent Citations (3)
Title |
---|
A review of the literature on common CYP17A1 mutations in A review of the literature on common CYP17A1 mutations in series of such mutations among Koreans and functional characteristics of a novel mutation;Yoo-Mi Kim等;《Metabolism Clinical and Experimental》;20141231;第63卷;第45页右栏第1段 * |
Jun Yang等.Phenotype-Genotype Correlation in Eight Chinese 17α-Hydroxylase/17,20 Lyase-Deficiency Patients with Five Novel Mutations of CYP17A1 Gene.《The Journal of Clinical Endocrinology & Metabolism》.2006,第91卷(第9期),3619–3625. * |
基因型明确的17,20-裂解酶缺陷症杂合子肾上腺皮质功能的研究;乔杰;《中华内分泌代谢杂志》;20100831;第26卷(第8期);633-638 * |
Also Published As
Publication number | Publication date |
---|---|
CN106884041A (zh) | 2017-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Trynka et al. | Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-κB signalling | |
Coppieters et al. | Identity-by-descent–guided mutation analysis and exome sequencing in consanguineous families reveals unusual clinical and molecular findings in retinal dystrophy | |
Choi et al. | Gene expression and genetic variation data implicate PCLO in bipolar disorder | |
CN104862380B (zh) | 家族特异性遗传病关联等位基因单体型变异标签确认方法 | |
Li et al. | Loci with genome-wide associations with schizophrenia in the Han Chinese population | |
Shen et al. | Preimplantation genetic diagnosis for α-and β-double thalassemia | |
Geretz et al. | Full-length next-generation sequencing of HLA class I and II genes in a cohort from Thailand | |
Singh et al. | Combination of low producer AA-genotypes in IFN-γ and IL-10 genes makes a high risk genetic variant for HIV disease progression | |
Ngow et al. | CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia | |
Schol-Gelok et al. | A genome-wide screen for depression in two independent Dutch populations | |
Taskesen et al. | Novel Alu retrotransposon insertion leading to Alstrom syndrome | |
CN106884041B (zh) | 适用于中国人群的17α羟化酶缺乏症常见基因突变的检测方法 | |
Soejima et al. | Genetic variation of FUT2 in a Vietnamese population: identification of two novel Se enzyme–inactivating mutations | |
Ridruechai et al. | Association analysis of susceptibility candidate region on chromosome 5q31 for tuberculosis | |
Katiraee et al. | Sequences type analysis of Candida albicans isolates from Iranian human immunodeficiency virus infected patients with oral candidiasis | |
Zhang et al. | Gene variation in IL10 and susceptibility to chronic hepatitis B | |
Bliskunova et al. | Association of MGAT4C with major neurocognitive disorder in the Mexican population | |
Yang et al. | Association study between interleukin-1β gene (IL-1β) and schizophrenia | |
Kwon et al. | Genetic associations of mitochondrial DNA polymorphisms with Behçet's disease in a Korean population: A pilot study | |
Maheshwari et al. | Common and rare variants of DAOA in bipolar disorder | |
Vlckova et al. | Monozygotic twins with 17q21. 31 microdeletion syndrome | |
CN107475423B (zh) | 无头精子症新致病基因及其应用 | |
CN108486230A (zh) | 用于无创检测mitf基因突变的试剂盒及其制备方法 | |
Kortunay et al. | Association of a genetic polymorphism of the alcohol-metabolizing enzyme ADH1C with alcohol dependence: Results of a case-control study | |
Saeed et al. | POLYMORPHISMS IN THE ACE2 AND IL-6 GENES AND THEIR POTENTIAL IMPACT ON THE SUSCEPTIBILITY OF SEVERE COVID-19 AMONG ERBIL HOSPITALIZED PATIENTS: Polymorphisms in the ACE2 and IL-6 genes and COVID-19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |